PPTA Twitter

PlasmaProteins Next month, @PlasmaProteins will hold its annual Fly-In on Capitol Hill! PPTA, its membership, and stakeholders will advocate for patient protections & the importance of prohibitions on lifetime and annual caps for people who need #plasmaprotein therapies. bit.ly/2FRKqnR
About 4 hours ago.
PlasmaProteins Today marks #WorldHemophiliaDay . Hemophilia A affects 1 in 10,000 people; hemophilia B is less common & affects just 1 in 25,000. Today we raise awareness of those living with these rare conditions and the #plasmaprotein therapies used to help them live a healthier life. #WHD2019 pic.twitter.com/IJ8MZiqYNA
1 day ago.

PPTA Presents in Malta

During the biannual Plasma Product Biotechnology Meeting held 15-19 May in Malta, PPTA was invited to make two presentations:

"The World Needs Plasma from the USA and Other Countries" described the importance of U.S. plasma for the manufacturing of plasma protein therapies in the world, the need to remove restrictions on Source plasma collections in other countries and a better use of recovered plasma to meet patient needs.

"Source Plasma Safety" addressed the various steps in donor screening and the value of Source Industry standards for Qualified donors, Inventory hold, and viral marker rates. Residual risk of a window period donation entering the manufacturing pool was discussed. as well as the effectiveness of viral inactivation/ removal were also presented.

Both presentations are available on our website.

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100